PMID- 32557321
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20240207
IS  - 1937-5395 (Electronic)
IS  - 1937-5387 (Linking)
VI  - 13
IP  - 6
DP  - 2020 Dec
TI  - Admission Low-Density Lipoprotein Cholesterol Stratified by Circulating 
      CD14++CD16+ Monocytes and Risk for Recurrent Cardiovascular Events Following ST 
      Elevation Myocardial Infarction: Lipid Paradox Revised.
PG  - 916-927
LID - 10.1007/s12265-020-10015-6 [doi]
AB  - Lower level of low-density lipoprotein cholesterol (LDL-C) is paradoxically 
      associated with increased mortality in ST elevation myocardial infarction (STEMI) 
      patients. The underlying mechanism remains unclear. In a cohort of 220 de novo 
      STEMI patients receiving timely primary percutaneous coronary intervention, 
      admission LDL-C was negatively associated with circulating CD14++CD16+ monocyte 
      counts. Moreover, admission LDL-C < 85 mg/dL was associated with increased risk 
      for major adverse cardiovascular events (MACE) during a median follow-up of 
      2.7 years. After categorizing the patients according to the cutoff values of 
      85 mg/dL for LDL-C and the median for CD14++CD16+ monocytes, low LDL-C-associated 
      MACE risk was only observed in those with high CD14++CD16+ monocyte counts (low 
      LDL-C/high CD14++CD16+ monocytes vs. low LDL-C/low CD14++CD16+ monocytes: hazard 
      ratio 5.38, 95% confidence interval 1.52 to 19.06, P = 0.009). This work provided 
      the proof-of-principle evidence indicating a role of CD14++CD16+ monocytes in 
      risk stratification of STEMI patients presenting with low LDL-C level. Graphical 
      abstract.
FAU - Dong, Shaozhuang
AU  - Dong S
AD  - Department of Cardiology, Tianjin Medical University General Hospital, 154, 
      Anshan Road, Heping District, Tianjin, 300052, China.
FAU - Ji, Wenjie
AU  - Ji W
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Zeng, Shan
AU  - Zeng S
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Miao, Jun
AU  - Miao J
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Yan, Lifang
AU  - Yan L
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Liu, Xinlin
AU  - Liu X
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Liu, Junxiang
AU  - Liu J
AD  - Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, 
      Heart Center, Pingjin Hospital, Tianjin, China.
FAU - Zhou, Xin
AU  - Zhou X
AUID- ORCID: 0000-0003-1395-7103
AD  - Department of Cardiology, Tianjin Medical University General Hospital, 154, 
      Anshan Road, Heping District, Tianjin, 300052, China. xzhou@live.com.
FAU - Yang, Qing
AU  - Yang Q
AD  - Department of Cardiology, Tianjin Medical University General Hospital, 154, 
      Anshan Road, Heping District, Tianjin, 300052, China. cardio-yq@tmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
PL  - United States
TA  - J Cardiovasc Transl Res
JT  - Journal of cardiovascular translational research
JID - 101468585
RN  - 0 (Biomarkers)
RN  - 0 (CD14 protein, human)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (FCGR3B protein, human)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cholesterol, LDL/*blood
MH  - Female
MH  - GPI-Linked Proteins/blood
MH  - Humans
MH  - Immunity, Innate
MH  - Lipopolysaccharide Receptors/*blood
MH  - Male
MH  - Middle Aged
MH  - Monocytes/immunology/*metabolism
MH  - *Patient Admission
MH  - Percutaneous Coronary Intervention/adverse effects
MH  - Proof of Concept Study
MH  - Receptors, IgG/*blood
MH  - Recurrence
MH  - Risk Assessment
MH  - Risk Factors
MH  - ST Elevation Myocardial Infarction/*blood/diagnosis/immunology/therapy
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Lipid paradox
OT  - Low-density lipoprotein cholesterol
OT  - Monocyte subsets
OT  - Prognosis
OT  - ST elevation myocardial infarction
EDAT- 2020/06/20 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s12265-020-10015-6 [pii]
AID - 10.1007/s12265-020-10015-6 [doi]
PST - ppublish
SO  - J Cardiovasc Transl Res. 2020 Dec;13(6):916-927. doi: 10.1007/s12265-020-10015-6. 
      Epub 2020 Jun 18.